LAZCLUZE·RYBREVANT Combo: A Game Changer for EGFR Mutant Lung Cancer
The combination therapy of LAZCLUZE(Lazertinib) and RYBREVANT(Amivantamab) has demonstrated superior effectiveness compared to existing monotherapies in treating atypical EGFR mutation non-small cell lung cancer (NSCLC). A study led by Professor…